Squamous Cell Carcinoma Clinical Trial
Official title:
Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue
Patients enrolled for the study, who are eligible for NACT, will undergo a pre-treatment
workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and tissue biopsy
along with a PET-CT scan. Subsequently, they would undergo 3 cycles of NACT (weekly thrice)
with DCF. They would be reassessed with PET-CT and EUA +/- biopsy after the end of the third
cycle. Those who are achieving CR would undergo adjuvant CTRT. Subjects who have a PR in the
PET-CT scan will be re-classified based on the biopsy report. If they remain in the PR group
they will undergo surgery but if the biopsy in is negative for malignancy, they will undergo
adjuvant CTRT. Those subjects with SD or PD would undergo surgery. Subsequently, further
radiation and/ or chemotherapy will be decided based on the final histopathology (of the
surgical specimen) reports.
PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment
completion.
Patients enrolled for the study, who are eligible for Neoadjuvant chemotherapy, will undergo
a pre-treatment workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and
tissue biopsy along with a PET-CT scan. Subsequently, they would undergo 3 cycles of
Neoadjuvant chemotherapy (weekly thrice) with injection Docetaxel, Cisplatin, and 5-FU. They
would be reassessed with PET-CT and EUA +/- biopsy after the end of the third cycle. Those
who are achieving a Complete Response (CR) would undergo adjuvant chemo-radiotherapy.
Subjects who have a partial response (PR) in the PET-CT scan will be re-classified based on
the biopsy report. If they remain in the PR group they will undergo surgery. If the biopsy
in these patients is negative for malignancy, they will undergo adjuvant chemoradiotherapy.
Those subjects with stable disease (SD) or progressive disease (PD) would undergo surgery.
Subsequently, further radiation and/ or chemotherapy will be decided based on the final
histopathology (of the surgical specimen) reports.
PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment
completion.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02213133 -
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT04533321 -
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Active, not recruiting |
NCT01232374 -
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01208883 -
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
|
Phase 1 | |
| Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
| Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
| Terminated |
NCT00707655 -
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
|
Phase 1/Phase 2 | |
| Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
| Completed |
NCT01127737 -
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
|
N/A | |
| Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
| Completed |
NCT00409565 -
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00176267 -
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
|
Phase 2 | |
| Terminated |
NCT04685798 -
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
|
N/A | |
| Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
| Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Not yet recruiting |
NCT05852665 -
Buccal Cancer Resection Ultrasound Guided
|
N/A | |
| Recruiting |
NCT05048459 -
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
|
N/A | |
| Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 |